122 related articles for article (PubMed ID: 38787978)
21. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets.
Vernemmen AIP; Samarska IV; Speel EM; Riedl RG; Goudkade D; de Bruïne AP; Wouda S; van Marion AM; Verlinden IV; van Lijnschoten I; Friederich P; Winnepenninckx VJL; Zur Hausen A; Sciot RME; van den Hout MFCM
Histopathology; 2024 Apr; 84(5):794-809. PubMed ID: 38155480
[TBL] [Abstract][Full Text] [Related]
22. ALK-negative lung inflammatory myofibroblastic tumor in a young adult: A case report and literature review of molecular alterations.
Debonis SA; Bongiovanni A; Pieri F; Fausti V; De Vita A; Riva N; Gurrieri L; Vanni S; Diano D; Mercatali L; Ibrahim T
Medicine (Baltimore); 2021 May; 100(20):e25972. PubMed ID: 34011083
[TBL] [Abstract][Full Text] [Related]
23. Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor.
Debelenko LV; Arthur DC; Pack SD; Helman LJ; Schrump DS; Tsokos M
Lab Invest; 2003 Sep; 83(9):1255-65. PubMed ID: 13679433
[TBL] [Abstract][Full Text] [Related]
24. [Inflammatory myofibroblastic tumor].
Leuschner I
Pathologe; 2010 Mar; 31(2):106-8. PubMed ID: 20063099
[TBL] [Abstract][Full Text] [Related]
25. Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition.
Reinhart S; Trachsel Y; Fritz C; Wagner U; Bode-Lesniewska B; John H; Pless M
Urology; 2020 Dec; 146():32-35. PubMed ID: 33007314
[TBL] [Abstract][Full Text] [Related]
26. Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review.
Zhang L; Luan L; Shen L; Xue R; Huang J; Su J; Huang Y; Xu Y; Wang X; Shao Y; Ji Y; Xu C; Hou Y
Virchows Arch; 2023 Mar; 482(3):567-580. PubMed ID: 36624188
[TBL] [Abstract][Full Text] [Related]
27. Inflammatory myofibroblastic tumor: molecular landscape, targeted therapeutics, and remaining challenges.
Mahajan P; Casanova M; Ferrari A; Fordham A; Trahair T; Venkatramani R
Curr Probl Cancer; 2021 Aug; 45(4):100768. PubMed ID: 34244015
[TBL] [Abstract][Full Text] [Related]
28. ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.
Brivio E; Zwaan CM
Pediatr Blood Cancer; 2019 May; 66(5):e27645. PubMed ID: 30697903
[TBL] [Abstract][Full Text] [Related]
29. Pregnancy-associated Inflammatory Myofibroblastic Tumors of the Uterus Are Clinically Distinct and Highly Enriched for TIMP3-ALK and THBS1-ALK Fusions.
Devereaux KA; Fitzpatrick MB; Hartinger S; Jones C; Kunder CA; Longacre TA
Am J Surg Pathol; 2020 Jul; 44(7):970-981. PubMed ID: 32271187
[TBL] [Abstract][Full Text] [Related]
30. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
31. Anaplastic Lymphoma Kinase Inhibitor in Treatment of Inflammatory Myofibroblastic Tumor of the Tongue in Infancy.
Rao K; Farooki S; Guest E; Chastain K; Gener M; Akangire G
J Pediatr Hematol Oncol; 2021 May; 43(4):e521-e524. PubMed ID: 32769570
[TBL] [Abstract][Full Text] [Related]
32. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
[TBL] [Abstract][Full Text] [Related]
33. ALK-negative urachal inflammatory myofibroblastic tumor in an elderly female: A case report.
Wang K; Zhou H; Lu Y; Lu Q; Zhang C; Zhou X; Xia S; Wang G
Medicine (Baltimore); 2018 Dec; 97(51):e13619. PubMed ID: 30572472
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall.
Kerr DA; Thompson LDR; Tafe LJ; Jo VY; Neyaz A; Divakar P; Paydarfar JA; Pastel DA; Shirai K; John I; Seethala RR; Salgado CM; Deshpande V; Bridge JA; Kashofer K; Brčić I; Linos K
Am J Surg Pathol; 2021 Dec; 45(12):1707-1719. PubMed ID: 34001695
[TBL] [Abstract][Full Text] [Related]
35. Inflammatory myofibroblastic tumor and low-grade myofibroblastic sarcoma: a comparative study of clinicopathologic features and further observations on the immunohistochemical profile of myofibroblasts.
Qiu X; Montgomery E; Sun B
Hum Pathol; 2008 Jun; 39(6):846-56. PubMed ID: 18400254
[TBL] [Abstract][Full Text] [Related]
36. Primary inflammatory myofibroblastic tumour of the liver: a clinicopathological and genetic study including a subset with ETV6::NTRK3 fusion.
Han Q; Zhang Z; He X; Chen M; Pang X; Chen C; Du T; Zhang H
Histopathology; 2023 May; 82(6):925-936. PubMed ID: 36748182
[TBL] [Abstract][Full Text] [Related]
37. Outstanding Response in a Patient With ROS1-Rearranged Inflammatory Myofibroblastic Tumor of Soft Tissues Treated With Crizotinib: Case Report.
Comandini D; Catalano F; Grassi M; Pesola G; Bertulli R; Guadagno A; Spina B; Mascherini M; De Cian F; Pistoia F; Rebuzzi SE
Front Oncol; 2021; 11():658327. PubMed ID: 34211840
[TBL] [Abstract][Full Text] [Related]
38. A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.
Kimbara S; Takeda K; Fukushima H; Inoue T; Okada H; Shibata Y; Katsushima U; Tsuya A; Tokunaga S; Daga H; Okuno T; Inoue T
Jpn J Clin Oncol; 2014 Sep; 44(9):868-71. PubMed ID: 25028698
[TBL] [Abstract][Full Text] [Related]
39. Inflammatory myofibroblastic tumor of bone harboring an ALK gene amplification.
Wang K; Guo R; Siegal GP; Wei S
Pathol Res Pract; 2019 Sep; 215(9):152535. PubMed ID: 31326196
[TBL] [Abstract][Full Text] [Related]
40. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.
Fischer M; Moreno L; Ziegler DS; Marshall LV; Zwaan CM; Irwin MS; Casanova M; Sabado C; Wulff B; Stegert M; Wang L; Hurtado FK; Branle F; Geoerger B; Schulte JH
Lancet Oncol; 2021 Dec; 22(12):1764-1776. PubMed ID: 34780709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]